Tocilizumab monotherapy uncovered the role of the CCL22/17-CCR4⁺ Treg axis during remission of crescentic glomerulonephritis.

ABSTRACT:

Objectives

Tocilizumab (TCZ) is a humanised anti-interleukin (IL)-6 receptor (IL-6R) monoclonal antibody that is a promising agent to treat various autoimmune diseases. However, the mechanism of TCZ efficacy is unclear. This study aims to elucidate the relationship between Tregs and IL-6R blockade in autoimmunity-mediated renal disease based on a TCZ-treated cohort of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and in an experimental model of crescentic glomerulonephritis (cGN).

Methods

We examined multiple serum levels of cytokines and chemokines and peripheral blood mononuclear cells in patients with AAV who received TCZ monotherapy and achieved drug-free remission. Moreover, we investigated the mechanistic role of IL-6R blockade i

SUBMITTER: Sakai R 

PROVIDER: S-EPMC7596393 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature